In this episode of "Rx for Biotech", host Chris Leidli speaks with Rodney Gillespie, Senior Vice President and U.S. Therapeutic Area Head for Oncology at Novartis, about the rapid evolution of prostate cancer care, including the rise of radioligand therapy and PSMA-targeted treatments like Pluvicto® (lutetium Lu 177 vipivotide tetraxetan).We discuss:* How PSMA-targeted radioligand therapy delivers radiation directly to cancer cells* The role of innovation in advanced and metastatic prostate cancer* Expanding patient access to cutting-edge therapies* Why patient advocacy and education matter in modern oncologyAs prostate cancer remains one of the most common cancers in men, new treatment approaches like radioligand therapy are redefining what’s possible for patients living with advanced prostate cancer.